Translational Model‐Informed Dose Selection for Iruplinalkib, a Selective Oral ALK / ROS1 Tyrosine Kinase Inhibitor

Ähnliche Einträge

• Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors
  von: Guihong Yang, et al.
  Veröffentlicht: (2024)
• Inter‐Ethnic Differences in the Efficacy and Safety of Tyrosine Kinase Inhibitors Used in Oncology: Insights From Phase 3 Clinical Trials
  von: Nicki M. Kyriacou, et al.
  Veröffentlicht: (2025)
• Early Development of Ocadusertib, a Selective Receptor‐Interacting Serine/Threonine‐Protein Kinase 1 Inhibitor
  von: Simon J. Shaw, et al.
  Veröffentlicht: (2026)
• Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell‐Derived Cardiomyocytes and FDA Adverse Events Reporting System
  von: Shota Yanagida, et al.
  Veröffentlicht: (2025)
• The role of acetylation and deacetylation in cancer metabolism
  von: Cuicui Wang, et al.
  Veröffentlicht: (2025)